PDCD1 and neoplasm: To assess the non-specificity in the improvement of L.p R3 to MC38 colon cancer mouse model, CT26 colon cancer, H22 liver cancer, and LLC lung cancer mouse model were further established to assess oral administration of L.p R3 and combinatorial treatment of L.p R3 with PD-1 in other tumor treatments.